奥布替尼治疗复发或难治性套细胞淋巴瘤:一项1/2期、开放标签、多中心、单臂研究
这项1/2期开放标签多中心单臂研究纳入复发或难治性套细胞淋巴瘤患者,评估奥布替尼的疗效与安全性。患者接受奥布替尼150 mg每日一次(n=86)或100 mg每日两次(n=20),中位随访23.8个月后总缓解率为81.1%,完全缓解率27.4%,部分缓解率53.8%。奥布替尼显示出显著疗效且耐受性良好。
要点
- 奥布替尼150 mg每日一次被选为推荐的2期剂量。
- 中位随访23.8个月,总缓解率81.1%,完全缓解27.4%,部分缓解53.8%。
- 中位缓解持续时间22.9个月,中位无进展生存期22.0个月,24个月总生存率74.3%。
核心结论
- 奥布替尼在复发或难治性套细胞淋巴瘤患者中显示出显著疗效且耐受性良好。
研究设计与样本
- 1/2期、开放标签、多中心、单臂研究,纳入复发或难治性套细胞淋巴瘤患者。
- 患者接受口服奥布替尼150 mg每日一次(n=86)或100 mg每日两次(n=20),直至疾病进展或出现不可接受的毒性。
- 既往治疗方案中位数为2(范围1-4),中位年龄62岁(范围37-73岁)。
- 150 mg每日一次被选为推荐的2期剂量。
- 试验注册号为NCT03494179。
主要发现
- 中位随访23.8个月后,总缓解率为81.1%,其中27.4%达到完全缓解,53.8%达到部分缓解。
- 中位缓解持续时间为22.9个月,中位无进展生存期为22.0个月。
- 中位总生存期未达到,24个月总生存率为74.3%。
- 发生率>20%的不良事件包括血小板减少症(34.0%)、上呼吸道感染(27.4%)和中性粒细胞减少症(24.5%)。
- ≥3级不良事件不常见,最常见包括血小板减少症(13.2%)、中性粒细胞减少症(8.5%)和贫血(7.5%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Relapsed or refractory (r/r) mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a poor prognosis. Bruton tyrosine kinase (BTK) is a mediator of B-cell receptor signaling and is associated with the development of B-cell lymphomas. Patients with r/r MCL were enrolled in this phase 1/2 study and treated with orelabrutinib, a novel, highly selective BTK inhibitor. The median number of prior regimens was 2 (range, 1-4). The median age was 62 years (range, 37-73 years). Eligible patients received oral orelabrutinib 150 mg once daily (n = 86) or 100 mg twice daily (n = 20) until disease progression or unacceptable toxicity. A dose of 150 mg once daily was chosen as the preferred recommended phase 2 dose. After a median follow-up duration of 23.8 months, the overall response rate was 81.1%, with 27.4% achieving a complete response and 53.8% achieving a partial response. The median duration of response and progression-free survival were 22.9 and 22.0 months, respectively. The median overall survival (OS) was not reached, and the rate of OS at 24 months was 74.3%. Adverse events (AEs) occurring in >20% of patients were thrombocytopenia (34.0%), upper respiratory tract infection (27.4%), and neutropenia (24.5%). Grade ≥3 AEs were infrequent and most commonly included thrombocytopenia (13.2%), neutropenia (8.5%), and anemia (7.5%). Three patients discontinued treatment because of treatment-related adverse events (TRAEs), but no fatal TRAEs were reported. Orelabrutinib showed substantial efficacy and was well tolerated in patients with r/r MCL. This trial was registered at www.clinicaltrials.gov as #NCT03494179.
引用
- Deng LJ, Zhou KS, Liu LH, et al. Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study. Blood Adv. 2023. PMID: 37078706. doi:10.1182/bloodadvances.2022009168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。